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ABSTRACT 33 
The human microbiota, which plays an important role in health and disease, uses 34 
complex carbohydrates as a major source of nutrients. Utilization hierarchy 35 
indicates that the host glycosaminoglycans heparin and heparan-sulfate are high 36 
priority carbohydrates for Bacteroides thetaiotaomicron, a prominent member of 37 
the human microbiota. The sulfation patterns of these glycosaminoglycans are 38 
highly variable, which presents a significant enzymatic challenge to the 39 
polysaccharide lyases and sulfatases that mediate degradation. It is possible that 40 
the bacterium recruits lyases with highly plastic specificities, expresses a repertoire 41 
of enzymes that target sub-structures of the glycosaminoglycans with variable 42 
sulfation, or the glycans are desulfated prior to cleavage by the lyases. To 43 
distinguish between these mechanisms the components of the B. thetaiotaomicron 44 
heparin/heparan sulfate degrading apparatus were analyzed.  The data showed 45 
that the bacterium expressed a single surface endo-acting lyase that cleaved 46 
heparan sulfate reflecting its higher molecular weight compared to heparin. Both 47 
heparin and heparan sulfate oligosaccharides imported into the periplasm were 48 
degraded by a repertoire of lyases, with each enzyme displaying specificity for 49 
substructures within these glycosaminoglycans that display a different degree of 50 
sulfation. Furthermore the crystal structures of a key surface glycan binding protein 51 
which is able to bind both heparin and heparan sulfate, and periplasmic sulfatases 52 
reveal the major specificity determinants for these proteins. The locus described 53 
here is highly conserved within the human gut Bacteroides indicating that the 54 
model developed is of generic relevance to this important microbial community.      55 
 56 
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SIGNIFICANCE STATEMENT 64 
The major nutrients available to the human microbiota are complex carbohydrates. 65 
Host glycans are important to this microbial community particularly when dietary 66 
carbohydrates are scarce. The host glycans heparin and heparan sulfate are high 67 
priority carbohydrates for Bacteroides thetaiotaomicron, a member of the human 68 
microbiota. The degradation of these complex carbohydrates is challenging, 69 
reflecting their highly variable sulfation patterns. How bacteria have adapted to 70 
depolymerize the myriad of substructures of this important class of 71 
glycosaminoglycan is unknown. Here we show how enzyme consortia, displaying 72 
complementary functions, target the different features of these host glycans. 73 
Structural data reveal that the acidic groups of the glycans are key specificity 74 
determinants for enzymes and binding proteins that comprise the degradative 75 
apparatus. 76 
 77 
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INTRODUCTION 95 
The vast microbial community resident in the human distal gut, the colonic 96 
microbiota (CM), is crucial to health, with dysbiosis in this ecosystem linked to 97 
numerous disease states (1-4). The survival of individual microorganisms and 98 
hence the composition of the CM depends on their ability to access available 99 
nutrients in this densely populated and highly competitive environment. The major 100 
nutrients available to the colonic microbiota are glycans, derived from either the 101 
diet or the host itself. Thus, studying the mechanisms by which glycans are utilized 102 
by the gut microbiota is critical to understanding the drivers of the ecology of this 103 
microbial community, and how this process relates to human health.   104 
 105 
The major glycan degraders in the CM are the Bacteroidetes (5-8). These 106 
organisms degrade their target glycans initially through enzymes on the bacterial 107 
surface, while the oligosaccharides generated are imported into the periplasm 108 
where a repertoire of enzymes depolymerize these molecules into their constituent 109 
sugars. The genes encoding these enzyme systems are physically linked into loci 110 
termed polysaccharide utilization loci or PULs (9, 10). A significant proportion of 111 
the complex carbohydrates available to the CM are mammalian in origin (11). 112 
Despite this preponderance in the gut, our understanding of how the CM accesses 113 
host/mammalian glycans is fragmentary. Models for the breakdown of high 114 
mannose and complex N-glycans by gut Bacteroides have been proposed (12, 115 
13), and the ecological significance of removing terminal sialic acid from the 116 
epithelial mucosa is established (14). There is, however, a paucity of information 117 
on the mechanism by which glycosaminoglycans (GAGs) such as heparin and 118 
heparan sulfate (HS) are utilized by the microbiota. HS is a major component of 119 
the extracellular matrix of mammalian cells and is therefore likely to be available 120 
to the gut microbiota via turnover of epithelial cells, or from ingested meat products 121 
(15-17). Heparin is found exclusively in mast cells and is released at sites of injury 122 
so may not be as prevalent as HS in the gut (17-19). 123 
 124 
 125 
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Microbial utilization of heparin and HS poses significant biological challenges. Both 126 
glycans differ significantly in their degree of polymerization, which suggests 127 
degradation may occur in different cellular locations, while sulfation patterns and 128 
the nature of the UA are also highly variable (Fig. 1; and see Results Section). 129 
This substantial heterogeneity indicates that either a complex portfolio of enzymes 130 
is required to deconstruct these acidic glycans, or the enzymes that mediate this 131 
process display significant substrate promiscuity. The depolymerization of uronic 132 
acid (UA) containing glycans such as heparin and HS is mediated by glycoside 133 
hydrolases (GHs) and/or polysaccharide lyases (PLs) that are grouped into 134 
sequence-based families in the CAZy database (20). With respect to heparin and 135 
HS, PLs belonging to families PL12, 13 and 21 from different bacteria cleave the 136 
linkages in these GAGs. Indeed, based on specificity, these PLs that target heparin 137 
and HS can be further broadly grouped into Hep I, II and III.  Hep I lyases require 138 
sulfation, Hep II PLs exhibit a degree of promiscuity with respect to sulfation 139 
patterns  and Hep III enzymes cleave low sulfation regions of these GAGs (21, 22). 140 
The lyases generate products capped by ∆4,5-unsaturated UA (∆UA), which is  141 
released from the GAG by GHs from family GH88 (23, 24). In addition, some GAG-142 
specific sulfatases have been characterized (25). 143 
 144 
Although enzymes active against heparin and HS have been described, how these 145 
lyases, GHs and sulfatases are tailored to act in unison to address the sulfation 146 
problem posed by these GAGs is unclear. Several scenarios can be proposed 147 
including desulfation prior to backbone cleavage, the exploitation of broad 148 
specificity PLs that can cleave heparin and HS independent of their sulfation, or 149 
the recruitment of a consortium of lyases with each enzyme targeting specific sub-150 
structures in these GAGs that differ in their sulfation profiles. Similarly, the 151 
mechanisms by which the cell-surface glycan binding proteins, which contribute to 152 
the glycan degradation machinery, are able to target conserved features of these 153 
heterogeneous glycans is unknown.  154 
 155 
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Bacteroides thetaiotaomicron (Bt), a prominent member of the CM, use heparin 156 
and HS as high priority nutrient sources and, surprisingly, activates a single PUL 157 
(PULHep) to mediate the utilization of these GAGs (26).  Here we have dissected 158 
the mechanism by which the enzymes and binding proteins encoded by this locus 159 
are able to fully deconstruct these highly variable GAGs, and thus solve the 160 
sulfation problem. Crystal structures of key proteins provide mechanistic insight 161 
into substrate and ligand recognition. The data revealed how the specificity of the 162 
apparatus is optimized to target the repertoire of GAG structures presented to the 163 
bacterium at the different stages of the degradative process. We discuss the 164 
relevance of our model of GAG metabolism to microbial survival in the human gut. 165 
 166 
RESULTS 167 
Structure of HS and heparin. Heparin and HS are composed of a disaccharide 168 
repeating unit comprising a UA, which can be D-glucuronic (GlcA) or L-iduronic 169 
acid (IdoA), alternating with D-glucosamine (GlcN). GlcN is linked α1,4 to the UA 170 
whilst IdoA and GlcA are linked α1,4 and β1,4, respectively to the amino sugar, 171 
(reviewed in (17)) (Fig. 1). In addition, GlcN can be sulfated, predominantly on N2 172 
and O6, or can be acetylated at N2 (GlcNAc), while the UAs are often sulfated on 173 
O2. Heparin contains significantly more IdoA than HS and is almost completely 174 
sulfated (Fig. 1). HS varies in its sulfation pattern, containing highly sulfated 175 
regions (heparin-like) and areas that contain little or no sulfation (Fig. 1). The 176 
degree of polymerization (DP) of heparin (~40) is substantially less than HS (~80-177 
200), reflecting differences in their post-biosynthetic processing by the mammalian 178 
endo-glucuronidase.  179 
 180 
PULHep structure. Bt grows on heparin, HS and N-acetyl-de-O-sulfated heparin 181 
(i.e. unsulfated; ΔSHep) as sole carbon sources (Fig. S1) (26, 27). Transcriptomics 182 
of Bt cultured on heparin indicate that only PULHep, extending from bt4652–bt4675, 183 
was upregulated in response to this GAG (26). The locus encodes a number of 184 
PLs, sulfatases, a GH88 and a member of the ‘Repressor, Open reading frame, 185 
Kinase’ (ROK; Pfam PF00480) family (Fig. 1). In addition the sulfatase BT1596 is 186 
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also upregulated by heparin (25). PULHep is regulated by a hybrid two-component 187 
system (HTCS) that recognizes heparin/HS-derived disaccharides (26, 27) and 188 
encodes a single SusC/SusD-like outer membrane glycan transporter system as 189 
well as a potential surface glycan binding protein (SGBP) (Fig. 1). In silico analysis 190 
of the occurance of PULHep in bacterial genomes suggests that it is widely 191 
distributed within the Bacteroides (Fig. S2) and, in comparison to other 192 
characterized PULs, retains relatively high sequence conservation and synteny (5, 193 
6). 194 
 195 
Surface glycan binding proteins. The extracellular location of the putative 196 
SGBP, BT4661, was confirmed using immunofluorescence with anti-BT4661 197 
antibodies against formaldehyde fixed cells as well as proteinase K treatment of 198 
whole cells (Fig S3A and B). Staining of wild type cells but not the ∆bt4661 199 
deletion mutant showed that the antibody bound specifically to BT4661 (Fig. S3A). 200 
The foci on glucose grown cells show stochastic expression of BT4661 throughout 201 
the population (~1/3 of the cells; 708/2016 cells counted), consistent with the idea 202 
that PULs are expressed at low levels in the absence of target glycan to scan the 203 
environment for substrate. Immunoprecipitation of BT4661 from heparin grown 204 
cells followed by western blotting revealed the presence of BT4659SusD-like, 205 
indicating that the two proteins physically associate. (Fig. S3C). The lower level of 206 
BT4659SusD-like compared to BT4661 in the immunoprecipitate either reflects 207 
differences in the expression levels of the two proteins or, more likely, a relatively 208 
weak association leading to the loss of BT4659SusD-like under the conditions used. 209 
The interaction between the PUL encoded SBGP and SusD-like is consistent with 210 
previous data from the starch utilization system of Bt and a canine oral 211 
Bacteroidetes (28, 29). The importance of BT4659SusD-like in heparin/HS utilisation 212 
was highlighted by the severe lag (>20h) displayed by ∆bt4659SusD-like on all three 213 
forms of the GAG tested (Fig S1A). By contrast ∆bt4661SGBP had no noticeable 214 
growth defect on HS or ΔSHep, but had a minor phenotype when cultured on 215 
heparin or, more noticeably, when heparin-derived oligosaccharides were the 216 
growth substrate (Fig. S1A, inset). This defect on oligosaccharides rather than 217 
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polysaccharide is similar to that observed with the B. ovatus xyloglucan SGBP 218 
deletion and it has been suggested this is due to the SGBP playing a role in 219 
oligosaccharide scavenging rather than polysaccharide acquisition (30). 220 
 221 
Glycan specificity: Isothermal titration calorimetry (ITC) was used to explore the 222 
binding specificity of BT4661SGBP as well as BT4659SusD-like. The data (Figure 2A 223 
and Table S1), revealed that BT4661SGBP bound tightly to both heparin and HS 224 
(Kd ~3 µM), but not to other GAGs. Notably, coverage on both heparin and HS 225 
was similar, suggesting the protein can tolerate both sulfated and unsulfated 226 
regions of the GAGs and could interact or accommodate the different UAs and 227 
neutral sugars in heparin and HS (see structures of GAGs in Fig 1). BT4661SGBP 228 
also interacted with fully sulfated heparin-derived oligosaccharides with a degree 229 
of polymerization (DP) ≥4, with affinity increasing up to DP 6 to a level similar to 230 
heparin. This indicates that the BT4661SGBP binding site can accommodate a 231 
hexasaccharide and supports the ability of the SGBP to tolerate/recognize 232 
sulfation and IdoA at all subsites (Table S1). Overall, these data support the 233 
hypothesis that BT4661SGBP is a SGBP of the heparin/HS degrading apparatus 234 
and that the protein displays plasticity in its recognition of heparin based GAGs.  235 
 236 
BT4659SusD-like bound heparin, HS and ∆SHep with similar affinity, but the Kd was 237 
~20-30 fold lower than for the BT4661SGBP. Differences in affinity between the 238 
SusD-like and cognate SGBP has been reported for other PULs, but to different 239 
degrees (6, 30). This could be to do with the proposed different roles these proteins 240 
play in glycan utilization, or simply that the affinity displayed by the SusD in vitro 241 
may not be related to the affinity in the cell as these proteins have been shown to 242 
be closely associated with their cognate SusC transporter that also contributes to 243 
ligand binding (31).  244 
 245 
Structure of full length BT4661SGBP: To understand the mechanism of ligand 246 
recognition, the crystal structure of BT4661SGBP was determined. The protein 247 
comprises six discrete domains that all adopt an Ig-like fold (Fig. 2B). This multi 248 
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Ig-like domain structure is common to the other three SGBPs whose structure is 249 
known, though little or no sequence identity is evident between these proteins (6, 250 
30, 32). The domains, defined as D1 (N-terminus) to D6 (C-terminus), are arranged 251 
in an extended, curved conformation. Inter-domain proline residues may limit the 252 
flexibility of the SGBP (30). Small Angle X-ray Scattering (SAXS) on full length 253 
BT4661SGBP in the presence and absence of heparin gave the same Rg and Dmax 254 
values for both conditions (Table S3), indicating no large conformational changes 255 
are imposed by the target GAG, although flexibility seems more constrained in the 256 
ligand bound form (NSD of 1.5) (Table S4, Fig. 2C and Fig. S3D). 257 
 258 
Structure of truncated BT4661SGBP bound to oligosaccharide: Attempts to obtain a 259 
complex of the full length BT4661 with heparin oligosaccharides were 260 
unsuccessful. Notably, however, a truncated form of the protein comprising only 261 
D5 and D6 displayed similar ligand binding to the wild type SGBP. The crystal 262 
structure of the D5/6 derivative (TrBT4661SGBP) was determined in complex with a 263 
fully sulfated, heparin-derived unsaturated hexasaccharide (∆4,5UA2S-GlcNS6S-264 
IdoA2S-GlcN6S-IdoA2S-GlcNS6S) (Fig. 2D, E and Fig. S4A). The binding site is 265 
formed across the D5 and D6 domains with the reducing end of the 266 
hexasaccharide, GlcNS6S, lying in D6 (subsite 1) and the non-reducing end 267 
∆IdoA2S located in D5 (subsite 6). D6 and D5 house sugars 1-4 and 5-6 of the 268 
hexasaccharide, respectively. The presence of the glycan binding site on the C-269 
terminal domain of an extended multi-domain SGBP has been observed previously 270 
and may be an adaptation to enable ligand binding to occur at a distance from the 271 
cell surface (30). Similar to other GAG binding proteins, interactions between 272 
ligand and protein mainly involved basic amino acids, rather than face to face 273 
stacking interactions between the sugar rings and aromatic residues that is the 274 
characteristic signature of protein-carbohydrate recognition involving non-charged 275 
glycans (17, 30, 32, 33). Alanine scanning mutagenesis revealed that K505, R581 276 
and R582 are the key residues involved in ligand binding (Figure S3E). R582 and 277 
K505 interact with the carboxylates of the uronic acid at subsites 2 and 6 278 
respectively, whilst R581 interacts with O3 of the reducing end sugar. These 279 
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interactions will be conserved in all heparin based GAGs, providing an explanation 280 
for the ability of BT4661 to recognize both HS and heparin with similar affinity.  281 
 282 
Enzymes encoded by PULHep. To dissect the role of the PULHep encoded lyases, 283 
sulfatases and GH in heparin and HS degradation by Bt, the activity of recombinant 284 
forms of the enzymes against different substrates was assessed and the growth 285 
of mutant strains lacking active forms of the enzymes on heparin, HS and ΔSHep 286 
determined (Fig S1B-F). 287 
 288 
Surface lyase BT4662PL12. Western blots of heparin grown Bt cells treated with 289 
proteinase K showed that BT4662PL12 was sensitive to the proteinase. Aerobic 290 
whole cell assays, which reports only on the activity of surface enzymes, showed 291 
that the pattern of reaction products closely match that of recombinant 292 
BT4662PL12 (Fig. S3B and Fig S5A). These data, and the presence of a type II 293 
signal peptide, show that BT4662PL12 is a lipoprotein located on the surface of Bt. 294 
The range of oligosaccharides generated during the early stages of GAG 295 
degradation points to an endo activity. In other characterized PULs a surface endo-296 
acting glycanase generates polysaccharide-derived oligosaccharides that are of 297 
an appropriate DP to be transported by the SusC/D-like apparatus (5-7, 12). The 298 
∆bt4662PL12 mutant of Bt displayed a partial but not complete growth defect on HS 299 
(Fig. S1B). This likely reflects the heterogeneity of the DP of the GAG, thus the 300 
smaller forms of this glycan were able to be transported into the periplasm of Bt 301 
without the need for prior depolymerization by the surface PL. Growth on heparin 302 
and ∆SHep was not impaired in the ∆bt4662PL12 mutant, reflecting their low DP, 303 
which likely enables these molecules to be transported into the periplasm without 304 
enzymatic processing on the bacterial outer membrane.  305 
 306 
Enzyme assays revealed that heparin was almost completely inaccessible to 307 
BT4662PL12 (only ~5% degradation), whilst the depolymerization of HS and ΔSHep 308 
was ~40 % and ~80 % respectively (Table S6). Against HS the limit products 309 
comprised a range of small and large products, while complete degradation of 310 
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∆SHep generated oligosaccharides with a DP of 2–10 (Fig. 3A and Fig. 5SE). 311 
BT4662PL12 was only active against heparin oligosaccharides with a DP ≥10 (Table 312 
S5). Together these data suggest BT4662PL12 has a large substrate binding cleft, 313 
in which sulfate groups can only be accommodated at limited/specific positions, 314 
and the enzyme displays an endo mode of action, with limited processivity. These 315 
data are consistent with a role for the enzyme in depolymerizing high molecular 316 
weight GAGs, such as HS, at the bacterial surface.  317 
 318 
Periplasmic enzymes. 319 
Polysaccharide lyases: Based on the presence of type I signal peptides, western 320 
blots of proteinase K treated whole cells, and the product profiles of whole cell 321 
assays compared to that of the recombinant enzymes, the majority of the 322 
polysaccharide degrading enzymes encoded by PULHep are located in the 323 
periplasm (Fig S3B and S5A). All the lyases had a pH optimum between 6.0 and 324 
6.5 and none were inactivated by EDTA suggesting they are not metal dependent. 325 
A unifying feature of the three periplasmic PLs, BT4652PL15, BT4657PL12 and 326 
BT4675PL13, is the appearance of limit disaccharide products during the initial 327 
phase of degradation rather than a range of larger oligosaccharides (Fig. 3). This 328 
is indicative of a degree of processivity, and likely results in rapid production of the 329 
disaccharides that act as the signaling cue(s) required to upregulate PULhep (27). 330 
The three periplasmic lyases have differing preferences for heparin, HS and 331 
ΔSHep (described in detail below), reflecting the ability of Bt to use these three 332 
substrates.  333 
 334 
BT4657PL12 exhibited greatest activity against HS and could access ~50% of the 335 
polymer; whilst against heparin the lyase achieved only 27% of the maximal 336 
cleavage (Tables S5 and S6). The enzyme displayed slightly lower catalytic 337 
efficiency against ΔSHep but could completely degrade the GAG to a single 338 
unsulfated disaccharide species (Tables S5 and S6 and Fig 3B). During the initial 339 
degradation of ΔSHep, BT4657PL12 generated an extensive range of 340 
oligosaccharides with the disaccharide subsequently becoming the dominant 341 
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product (Fig 3B and Fig S5E). These data indicate that BT4657PL12 is an endo-342 
active enzyme with a degree of processivity. Analysis of the products generated 343 
from partially sulfated oligosaccharides showed that BT4657PL12 is unable to 344 
accommodate 2-O sulfation of UA in its active site (+1 subsite) explaining why the 345 
enzyme displayed limited activity against heparin (see also Supplementary 346 
Results Section 1).  347 
 348 
In contrast, BT4675PL13 displayed its highest activity against heparin and was 349 
inactive against ΔSHep, consistent with a previous study suggesting that sulfation 350 
was required for activity (Table S5) (34). The requirement for sulfation was also 351 
mirrored in the end point assays which showed almost complete digestion of 352 
heparin, but only ~50% of HS (Table S6). The mode of action of the PL13 enzyme 353 
was similar to BT4657PL12 generating a range of different size products indicative 354 
of an endo-mode of action, but with a much higher degree of processivity, 355 
generating UA2S-GlcNS6S as the dominant product early in the reaction (Fig. 3C).  356 
 357 
PL15 enzymes have not previously been implicated in heparin or HS breakdown, 358 
having so far only been shown to be alginate lyases (35). BT4652PL15, encoded by 359 
PULhep, was most active against fully sulfated heparin oligosaccharides with a DP 360 
of 4–10, and while it could cleave all three GAGs tested the enzyme displayed a 361 
~850-fold lower kcat/Km against ΔSHep, compared to heparin, indicating sulfation 362 
was key for optimal activity (Table S5). In addition, the relative proportion of each 363 
GAG degraded by BT4652PL15 was consistent with preferential targeting of the 364 
sulfated regions of the polysaccharides (Table S6). The enzyme generated three 365 
disaccharides from heparin, UA2S-GlcNS6S, UA2S-GlcNS and UA-GlcNS6S; and 366 
against HS an additional disaccharide, UA-GlcNAc6S. The disaccharide UA-367 
GlcNAc was produced only from ΔSHep (Fig. 3D). BT4652PL15 generated the same 368 
disaccharides against heparin and heparin oligosaccharides with a DP of 6–10; no 369 
intermediate products were observed during the initial stages of the reactions (Fig. 370 
3D). These data indicate the enzyme has an exclusively exo-processive mode of 371 
action and can accommodate sulfates at all positions of the substrate. However, 372 
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as sulfation is not essential for BT4652PL15 activity, the enzyme displays more 373 
substrate flexibility than BT4675PL13. 374 
 375 
The data described above suggest that BT4652PL15 and BT4675PL13 can target 376 
similar heavily O-sulfated regions of heparin and HS, although the PL15 enzyme 377 
can, in addition, cleave sparsely sulfated regions of these GAGs. Consistent with 378 
this view is the observation that mutant strains lacking BT4652PL15 or BT4675PL13 379 
displayed growth defects on heparin and to a lesser extent HS, but not ΔSHep 380 
(Fig. S1B-E). In stark contrast the growth properties of ∆bt4657PL12 revealed a 381 
significant role for BT4657PL12 in HS degradation. The lyase is likely cleaving areas 382 
low in sulfation through an endo-mode, creating a number of non-reducing ends 383 
that are targeted by BT4652PL15 and BT4675PL13. Overall the data presented here 384 
provide a biological context for the multiple lyases expressed by Bt in response to 385 
heparin and HS (see Discussion). In essence, the primary substrates for 386 
BT4675PL13 and BT4657PL12 were regions of the GAGs that were highly and poorly 387 
sulfated, respectively. The ∆bt4652PL15 strain had the strongest phenotype on 388 
heparin, while ∆bt4652PL15/∆bt4657PL12 displayed little growth on HS and a marked 389 
increase in the lag phase when cultured on ΔSHep (Fig S1D). These growth 390 
profiles suggest that BT4657PL12 and BT4675PL13 produce oligosaccharides that 391 
only BT4652PL15 can degrade, and thus the additional flexibility in recognition by 392 
the PL15 bridges the two complementary activities of the PL12 and PL13 enzymes.  393 
  394 
GH88 enzyme: BT4658GH88 belongs to a family of enzymes that cleave the 395 
glycosidic linkage between the ∆4,5-unsaturated UA and GlcN/GlcNAc 396 
disaccharides that are produced by the GAG lyases. The enzyme was not active 397 
when O2 of the UA was sulfated, but could accommodate sulfation at N2 or O6 of 398 
the neutral sugar, mirroring the binding specificity of the PULHep HTCS BT4663 399 
(Table S4) (27). The tuning of the specificity of the PUL encoded GH88 with that 400 
of its cognate HTCS is analogous to that observed in the Bt chondroitin sulfate 401 
PUL, consistent with the proposed key role the GH88 enzymes play in promoting 402 
the growth rate of Bt on different GAGs by controlling the rate of signal degradation 403 
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(23). Although BT4658GH88 displayed similar catalytic efficiencies against GlcNS 404 
and GlcNAc, the Km and kcat for the sulfated sugar was lower, suggesting that the 405 
N-linked sulfate makes a contribution to substrate binding, but restricts product 406 
departure leading to a reduction in kcat.  407 
 408 
O-sulfatases:  A previous study showed that BT15962S-Sulf and BT46566S-sulf are 409 
exo-acting O-sulfatases; BT15962S-Sulf targets the O2 sulfation of unsaturated UA 410 
at the non-reducing end of di- and oligo-saccharides, while BT46566S-sulf cleaves 411 
the O6-sulfate of the monosaccharides GlcNAc6S or GlcNS6S (Table S7) (25).  412 
Although there is high sequence identity of the active site region, making sulfatase 413 
sequences readily identifiable, the high variability of the rest of the sequence 414 
makes assigning glyco-specificity difficult. To explore the mechanism of substrate 415 
recognition the crystal structures of inactive forms of the two Bt O-sulfatases were 416 
determined in complex with their substrates. 417 
 418 
BT15962S-Sulf and BT46566S-sulf share a conserved α/β hydrolase fold comprising a 419 
single domain (Fig. 4). Both enzymes have a pocket topology with metal binding 420 
sites located at the base of the pocket. Calcium was modeled into the BT46566S-421 
sulf ligand bound structure whilst no metal was observed in BT15962S-Sulf (Fig 4A, 422 
4B and Fig. S4). Alanine substitution of the residues in this pocket to Ala 423 
inactivated both enzymes except for H25A in BT1596 (see Supplementary 424 
Results 2).  425 
 426 
Inactive forms of BT15962S-Sulf and BT46566S-sulf were co-crystallized with ∆UA2S-427 
GlcNS6S and GlcNS6S, respectively, revealing the molecular interactions 428 
between the enzymes and there substrates (Figs. 4A, 4B, S4B (i) and (ii)). 429 
BT15962S-Sulf and BT46566S  were inactive when expressed in Escherichia coli 430 
consistent with the inability of the enteric bacterium to convert S64 and S77, 431 
respectively into  formylglycine, which functions as the catalytic nucleophile [to 432 
generate the formylglycine in E. coli the catalytic serine was mutated to cysteine 433 
as the bacterium can convert cysteine to formylglycine (36)]. H188, in BT15962S-434 
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Sulf, and H196, in BT46566S, are both in close proximity to the scissile bond and the 435 
mutants H188A and H196A were completely inactive (Fig. 4A, 4B and Table S8). 436 
Given that histidine has a pKa of ~6.0, H188 and H196 are ideal candidates for the 437 
catalytic acid/base that is required to protonate the O2/O6 of the departing sugar 438 
following nucleophilic attack by the formylglycine and formation of a sulfate-439 
enzyme intermediate. The histidines then activate a water molecule that 440 
hydrolyzes the thioester linkage.   441 
 442 
In BT15962S-Sulf the carboxylate of ∆UA2S makes a bidentate ionic interaction with 443 
R237 and loss of this interaction (R237A mutant) results in a 2000-fold reduction 444 
in catalytic efficiency (Table S8). This interaction is likely the major specificity 445 
determinant used by the enzyme. This is consistent with the capacity of BT15962S-446 
Sulf to act on both chondroitin and heparin disaccharides, which both possess O2 447 
sulfated UA. In BT46566S R363 and D361, via Nη2 and Oδ1, respectively, 448 
coordinate O4 and mutation of R363 to Ala caused a ~500 fold decrease in activity 449 
whilst D361A was inactive (Table S8). These amino acids are likely specificity 450 
determinants for gluco over galacto configured substrates. Indeed if a 6-O and N-451 
sulfated galactosamine residue is modeled into the active site all interactions are 452 
preserved except for D361 and R363. Consistent with the importance of an 453 
equatorial O4 as a specificity determinant, BT46566S-sulf was inactive against 454 
sulfated galacto configured sugars (see Supplementary Results 2 for description 455 
of all mutants). 456 
 457 
N-sulfatase: There are no clear candidates for a sulfamidase gene in PULHep or 458 
indeed the rest of the genome. Bt, however, is able to utilize GlcNS as a sole 459 
carbon source. The only gene product in PULHep that shows no sequence identity 460 
with known CAZymes or sulfatases is BT4655. Significantly, the mutant ∆bt4655 461 
displayed a growth defect on sulfated GAGs but not on ΔSHep and accumulation 462 
of GlcNS in the culture medium was observed during growth on heparin and HS 463 
(Fig. S1F and Fig. S5F). These data strongly suggests that BT4655 cleaves the 464 
sulfamate linkage and is a new class of sulfatase to the three currently known (37-465 
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39). Unfortunately the proposed role of BT4655 as a sulfamidase could not be 466 
confirmed biochemically as a soluble recombinant form of the protein could not be 467 
generated. 468 
 469 
The data described here show that the activities of the three PULhep sulfatases is 470 
key for both heparin and HS breakdown. BT15962S-Sulf is the first to act, removing 471 
2-O sulfation from the limit disaccharide and oligosaccharide products of the PLs, 472 
allowing BT4658GH88 to hydrolyze its target linkage as this enzyme does not use 2-473 
O sulfated substrates. The sulfated glucosamine monosaccharides are then 474 
substrates for BT46566S-sulf and the likely N-sulfatase BT4655. BT46566S-sulf can 475 
tolerate both N-acetylation and N-sulfation and may act before BT4655NS-sulf (Table 476 
S7). 477 
 478 
Cytoplasmic sugar kinase. BT4654ROK is a member of the Repressor, ORF, 479 
Kinase (ROK) protein family that lacks a signal sequence and possesses the 480 
conserved DxGxT motif indicating that the protein is likely to be an ATP dependent 481 
kinase (40). This activity was confirmed by the capacity of the enzyme to utilize 482 
ATP to phosphorylate gluco and manno configured substrates but not galacto 483 
configured molecules (Table S7). The activity varied significantly for the different 484 
gluco configured substrates with kcat/Km decreasing from GlcN > GlcNAc >> 485 
Glc/Man >> GlcNS, which was driven by increases in Km (Table S7). These data 486 
demonstrate that O4 is critical for catalysis whilst strong selection in affinity is made 487 
at C2 for an equatorial amine, indicating that BT4654ROK uses both an equatorial 488 
N2 and O4 as specificity determinants. Significantly, the much lower activity of 489 
BT4654ROK against GlcNS compared to GlcN indicates that cleavage of the 490 
sulfamate precedes phosphorylation (Table S7). Despite the apparent importance 491 
of BT4654ROK in GlcNAc and GlcN metabolism, the ∆bt4654ROK mutant strain did 492 
not display a growth defect on the three GAGs tested (Fig. S1F), suggesting Bt 493 
displays redundancy in GlcN and GlcNAc phosphorylation. 494 
 495 
 496 
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DISCUSSION 497 
Bt PULHep orchestrates the hierarchical degradation of heparin and HS in this 498 
prominent gut bacterium. Both of these GAGs could be derived from dietary meat 499 
or host glycans. In vivo expression of PULHep in mice colonized with Bt has so far 500 
only been observed in bacteria occupying the mucosal layer, suggesting the 501 
source of heparin/HS available to Bt is from the turnover of epithelial cells rather 502 
than the diet (41). HS, however, could also be supplied in the human diet as a 503 
component of meat. To test this hypothesis we queried the colonic metagenomic 504 
data obtained in a study which swapped subjects from vegetarian, high-fiber diets, 505 
to meat rich diets, for the presence of any PL families associated with the 506 
degradation of heparin/HS (42). None were found in any subject on any diet, 507 
supporting the current hypothesis that the source of heparin/HS in the human gut 508 
that is accessible to the microbiota is from the turnover of epithelial cells. 509 
 510 
Within the heparin-based GAGs there is substantial structural diversity, especially 511 
in terms of the level of sulfation, and it is this heterogeneity that provides an 512 
explanation to the distinct but complementary activities of the enzymes encoded 513 
by the PULHep. A key feature of the PULHep degradative apparatus is the surface 514 
lyase, BT4662PL12, which, while dispensable for growth on heparin plays a 515 
significant role in optimal HS utilization. This likely reflects the high DP of HS, 516 
relative to heparin, and thus the GAG needs to be subjected to a degree of 517 
extracellular depolymerization to generate molecules that are small enough to be 518 
imported through the outer member SusC/SusD-like into the periplasm (6, 31).  519 
In the periplasm the substrate specificity of endo-processive lyases is optimized to 520 
target highly sulfated (BT4675PL13) or low/unsulfated regions (BT4657PL12), 521 
producing small oligosaccharides which, only the exo-processive lyase 522 
(BT4652PL15) is able to degrade. This role for BT4652PL15 is critical as loss of the 523 
enzyme means elements of both heparin and HS remain completely inaccessible. 524 
Indeed the presence of a PL15 seems to be a conserved feature of heparin/HS 525 
utilization in other Bacteroidetes analyzed, supporting its key role in breakdown of 526 
these GAGs (Fig. S2). The synergistic specificities displayed by the PULHep lyases 527 
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enables the bacterium to cleave the backbone of GAGs that display substantial 528 
structural variation, particularly in their sulfation patterns, leading to the generation 529 
of disaccharides. The disaccharides are broken down by the complementary 530 
activities of the sulfatases and the GH88 generating sugars that can then be 531 
metabolized by the bacterium after import into the cytoplasm. PULHep is activated 532 
by disaccharides of unsulfated ∆4,5UA linked to GlcN or GlcNAc in which N2 533 
and/or O6 can be sulfated, which are recognized in the periplasm by the PUL 534 
encoded HTCS BT4663 (27). Intriguingly BT4658 is predicted to be a lipoprotein, 535 
but based on its function can only be periplasmic rather than surface located. The 536 
attachment of this periplasmic enzyme to the membrane may be an adaptation 537 
based on the role the GH88 plays in breaking down the disaccharides that act as 538 
the PUL activation signals; by tethering the enzyme to the membrane the cell may 539 
be able to localize the GH88 to a discrete location in the periplasm, possibly away 540 
from the HTCS or co-located with the inner membrane transporter to maximize 541 
efficiency of sugar import (Fig. 1).  542 
 543 
Bt places a high priority on heparin and HS utilization demonstrated by the lack of 544 
repression of PULHep in the presence of other polysaccharides as well as glucose 545 
(43). HS represents an abundant source of GlcNAc, which is required for the 546 
synthesis of peptidoglycan. While Bt appears to contain all of the biosynthetic 547 
genes needed to make GlcNAc, it may still prioritize GlcNAc containing glycans as 548 
a nutrient source to fuel the production of its cell wall. As stated in Results, our 549 
current model suggests that the environmental signals that activate PULHep are 550 
derived from the mucosa rather than the diet. As the epithelium is likely to contain 551 
much higher amounts of HS compared to heparin, currently, we believe that the 552 
major biologically relevant glycan targeted by the enzyme system encoded by 553 
PULHep is HS and not heparin. Analysis of the genomes of other members of the 554 
human gut microbiota revealed Heparin/HS PULs similar to Bt (Fig S2). Indeed, 555 
B. xylanisolvens and B. ovatus both contain a predicted surface PL12 lyase (type 556 
II signal peptide) similar to BT4662PL12, suggesting that these organisms also 557 
target HS. In contrast the GAG degrading apparatus of B. intestinalis lacks an 558 
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obvious surface heparin/HS lyase (Fig S2). Thus, the bacterium may target 559 
oligosaccharides produced by other members of the microbiota or low molecular 560 
weight GAGs, such as heparin, which can be imported without the need for 561 
enzymatic depolymerization. 562 
   563 
The structural data of the sulfatases showed that the interactions with the target 564 
sulfate are highly conserved in BT15962S-sulf, BT46566S-sulf and the 6S GalNAc 565 
sulfatase GALNSase (Fig. S4C). In BT46566S-sulf and the GALNSase (the only 566 
other 6-O carbohydrate sulfatase for which a structure is available; PDB code 567 
4FDI), however, there is very little conservation in the residues that interact with 568 
the carbohydrate component of the substrate (Fig S4D), demonstrating this area 569 
is highly variable and could be the basis for bespoke highly specific glyco-sulfatase 570 
inhibitors. Such inhibitors may have therapeutic relevance as a recent study by 571 
Martens and colleagues showed that in a colitis-sensitive mouse model, sulfatases 572 
expressed by Bt are essential factors in inducing the disease (44).   573 
 574 
Conclusions: This report describes the comprehensive characterization of a PUL 575 
that orchestrates the degradation of heparin/HS GAGs, high priority heterogenous 576 
glycans. Unlike other microbial systems that remove side chains prior to backbone 577 
degradation, the glycan backbone of heparin/HS is depolymerized prior to removal 578 
of the sulfate groups. To achieve this Bt expresses lyases with complementary 579 
activities that in combination can fully deconstruct the heparin-based GAGs. 580 
Indeed the characterization of the PLs, sulfatases and GH provides an example of 581 
how this consortium of enzymes is bespoke for substrates that display highly 582 
variable sulfation patterns. Understanding the mechanisms by which gut bacteria 583 
depolymerize GAGs may provide crucial insights into how the human gut 584 
microbiota is adapted to utilize non-mucin host glycans and the role this process 585 
plays in colonization and survival in the gut. The model developed here can be 586 
harnessed to interrogate metagenomic data to explore the mechanisms by which 587 
different members of the CM metabolize these complex GAGs.  588 
 589 
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 590 
MATERIALS AND METHODS 591 
Sources of carbohydrates used. Heparin, N-Acetyl-de-O-sulfated heparin 592 
(∆SHep) and heparin-derived unsaturated oligosaccharides and disaccharides 593 
were from Dextra Laboratories Ltd (UK). Heparan sulfate (HS) was from Iduron Ltd 594 
(UK), or a kind gift from Prof J. Turnbull (University of Liverpool, UK). 595 
 596 
Bacteroides culture and genetic manipulation. Bacteroides thetaiotaomicron 597 
VPI-5482 was cultured anaerobically in a Whitley A35 Workstation (Don Whitley, 598 
UK) at 37 °C in either tryptone yeast extract glucose (TYG) medium or minimal 599 
medium (MM) as described previously (26). Bt strains containing specific gene 600 
deletions or inactivated versions of PULHep enzymes were made by counter 601 
selectable allelic exchange as described previously (45). Growth of wild type and 602 
mutants was measured on various glycans preparations by mixing the autoclave-603 
sterilised polysaccharides (1% final concentration) with minimal medium and 604 
monitoring growth continuously in 96 well plates using a Biotek Epoch plate reader. 605 
Growth curves presented are averages of three biological replicates. 606 
 607 
Enzyme assays. All assays, unless stated, were carried out in 50 mM MES pH6.0 608 
or BTP pH6.5 supplemented with 150 mM NaCl and 5 mM CaCl2. Polysaccharide 609 
lyase activity was monitored continuously at A235nm by the formation of the carbon 610 
double bond generated through the enzymes beta elimination mechanism of 611 
action. BT4658GH88 glucuronyl hydrolase activity was determined by monitoring 612 
loss of signal at A235nm. The ability of BT1596 to remove O2 sulfation from 613 
unsaturated heparin disaccharides was monitored continuously by the loss of 614 
signal at A235nm by linked assay using BT4658GH88, which is inactive on O2 sulfated 615 
unsaturated heparin disaccharides, to indirectly observe the loss of O2 sulfation. 616 
Activity of BT46566S-sulf to remove O6 sulfation from O6 sulfated GlcNac was 617 
monitored by the production of GlcNAc detected by high pressure anion exchange 618 
chromatography with pulsed amperometric detection (HPAEC-PAD), using 619 
carbohydrate standard quad waveform for electrochemical detection at a gold 620 
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working electrode with an Ag/AgCl pH reference electrode and a PA-100 Carbopac 621 
guard and analytical column (Dionex, ThermoFisher). An isocratic program with 622 
100 mM NaOH as the eluent was used. The ability of recombinant BT4654 kinase 623 
to phosphorylate various sugars including amino sugars was evaluated by 624 
performing sugar kinase assays as described previously (46). Briefly ADP 625 
generated by the transfer of phosphate to a sugar acceptor is used by pyruvate 626 
kinase to generate ATP and Pyruvate which is used by lactate dehydrogenase to 627 
oxidise NADH to NAD+ and thus loss of absorbance at 340nm can be used to 628 
indirectly monitor sugar phosphorylation by various kinases. Reaction profiles of 629 
PL digestion of various GAGs were monitored by HPAEC using an AD25 630 
absorbance detector at A235nm to detect the carbon double bond products. A 631 
Carbopac PA-100 guard and analytical column were used with H2O pH3.5 as the 632 
eluent and a second eluent of H2O with 3 M NaCl used to generate a linear NaCl 633 
gradient to 50 % over 80 minutes. For substrate depletion experiments the 634 
equation (kcat/KM).t=ln(S0/St) was used and the data fitted by linear regression. To 635 
determine all other kinetic data the initial rate vs a range of substrate 636 
concentrations was fit to the Michaelis-Menten equation by non-linear regression 637 
using Graphpad Prism 6.0. All assays were run in triplicate unless stated. 638 
 639 
Crystallization of BT1596, BT4661 and BT4656. After purification BT4661 was 640 
dialyzed against ultrapure H2O, whilst BT1596 and BT4656 were carried forward 641 
in the same eluent as used for the size exclusion chromatography. All proteins 642 
were then concentrated in centrifugal concentrators with a molecular weight cut off 643 
of 30 kDa.  Sparse matrix screens were setup in 96-well sitting drop TTP Labtech 644 
plates (400 nl drops). Initial BT1596 ligand bound crystals were obtained at 5 645 
mg/ml with 10 mM ligand in 20 % PEG 3350 and KCl. For BT4656 apo and ligand 646 
bound initial hits were obtained at 20 mg ml-1 in 2 M NH4SO4, 0.1 M Na Citrate pH 647 
5.6 and 0.2 M Rochelle salts and 20 % PEG 3350 and NaNO3, respectively. Apo 648 
BT4661 was crystallized at 10 mg ml-1 in 18-23% PEG 3350, 350 mM NaSO4, 0.1 649 
M Bis-Tris Propane, pH 8.0. Truncated BT4661 in was crystallized at 10 mg ml-1 650 
with 5 mM heparin hexasaccharide in 25% PEG 1500, 100 mM MMT pH 6. Data 651 
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were collected at Diamond Light Source (Oxford) on beamlines I02 and I04-1 (0.92 652 
Å) at 100 K. The data were integrated with XDS and scaled with Aimless. Five 653 
percent of observations were randomly selected for the Rfree set. The phase 654 
problem was solved by molecular replacement using the program Phaser for 655 
BT1596 with the PDB search model 3B5Q and the automated molecular 656 
replacement server Balbes for BT4656. The crystal structure of 4661 was solved 657 
using single-wavelength anomalous dispersion (SAD) based on the 658 
selenomethionine (SeMet) sites. The sites and phases were determined using 659 
SHELXC/D/E pipeline in CCP4i using intensities (47, 48). Due to the similarity in 660 
cell dimensions between the SeMet and the native crystal the phases from the 661 
SAD experiment could be transferred and extended to the higher resolution native 662 
dataset. The phase quality allowed us to use automated model-building with arp-663 
warp (49). The models were completed using iterative cycles of refinement with 664 
refmac5 and model-building using COOT (50, 51). The dataset obtained from a 665 
shorter construct of 4661 crystallised in presence of ligand was solved with Molrep 666 
using the corresponding PDB model from the native apo form (52). Solvent 667 
molecules were added using ARP/wARP solvent and checked manually. The 668 
model underwent cycles of model building in COOT and refinement in Refmac5 669 
(53). All other computing used the CCP4 suite of programs. The model was 670 
validated using MolProbity (54), and data statistics, refinement details and PDB 671 
codes are reported in Table S2. Structure representations were made using Pymol 672 
(version 1.74, Schrödinger). 673 
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FIGURE LEGENDS 834 
 835 
Figure 1. Model for degradation of heparin and HS by Bt. (A) Schematic of the 836 
PULHep locus in B. thetaiotaomicron. (B) Schematic representation of the cellular 837 
location, activity and specificity of the PULHep encoded enzymes and glycan 838 
binding proteins. A typical HS structure is shown. The proteins for which X-ray 839 
crystallographic structures were determined in this work are represented by 840 
thumbnail images of the structure. Briefly, heterogeneous heparan sulfate 841 
polysaccharides are cleaved into oligosaccharides by the surface PL12 BT4662. 842 
Heparins are shorter molecules and can be imported without prior cleavage The 843 
SGBP BT4661 and SusD-like protein BT4659 bind to heparin and HS 844 
oligosaccharides and orchestrate import through the SusC-like BT4660. In the 845 
periplasm, highly sulfated oligosaccharides are cleaved by the PL13 BT4675, and 846 
regions of low sulfation by the PL12 BT4657. The exo-acting PL15 BT4652 is able 847 
to bridge the two activities by producing unsaturated disaccharides from 848 
oligosaccharides of any sulfation pattern. Most of these disaccharides are 849 
specifically bound by the periplasmic sensor domains of the hybrid two-component 850 
system BT4663 (recognizes all except where the UA is 2-sulfated), which leads to 851 
upregulation of PULHep (27). The three sulfatases BT1596, BT4656 and BT4655 852 
(inset) remove 2S, 6S and NS sulfation, respectively, from either di- or mono-853 
saccharides. The GH88 BT4658 removes unsulfated 4,5 unsaturated uronic acid 854 
26  
from the disaccharides. The GlcN and GlcNAc products are imported into the 855 
cytoplasm (presumably through the inner membrane transporter BT4653) where 856 
they are substrates for the ROK kinase BT4654. 857 
 858 
Figure 2. Structural and biochemical characterization of the PULHep encoded 859 
surface glycan binding protein BT4661. (A) ITC traces for BT4661SGBP and 860 
BT4659SusD-like against HS and heparin. (B) Cartoon representation of BT4661SGBP 861 
colored from blue to red N- to C-terminus. Each of the six discrete domains is 862 
labelled. Grey spheres show the position of the inter-domain prolines. (C) SAXS 863 
envelopes (grey mesh) for apoBT4661 (upper panel) and BT4661 + heparin (lower 864 
panel). The best fit of the crystal structure of BT4661 (colored blue to red N- to C-865 
terminus) is shown inside the SAXS envelopes. (D) Structure of D5 and D6 C-866 
terminal domains of BT4661 bound to heparin hexasaccharide. (E) Ligand binding 867 
site of BT4661 bound to fully sulfated heparin derived hexasaccharide. Amino 868 
acids shown in green, sugars in yellow, H-bonds as black dotted lines. The 869 
residues labelled in red are critical for ligand recognition. The six sugar binding 870 
subsites are labelled 1-6 from the reducing end of the oligosaccharide. 871 
 872 
Figure 3. Product profile of the PULHep encoded polysaccharide lyases 873 
against heparin, HS and de-O-sulfated heparin. Peaks were identified by 874 
comparison to known standards at A235nm. Black lines represent zero time points 875 
whilst blue green and red represent early, mid and late points in the reaction time 876 
course. Reactions were carried out at 37°C in 50mM MES pH 6.0 with 150mM 877 
NaCl and 2mM CaCl2. 878 
  879 
Figure 4. Sulfatase structures. (A) and (B) upper panels are cartoon 880 
representations of BT15962S-sulf and BT46566S-sulf, respectively. (A) and (B) lower 881 
panels are stick representations of the active site interactions of BT15962S-sulf 882 
complexed with Δ4,5IdoA2Sβ1-4GlcNS6S and BT46566S-sulf complexed with 883 
GlcNS6S, respectively. 884 
 885 
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SUPPLEMENTAL METHODS 
 
Microscopy. Glucose grown cells were harvested at mid-exponential phase and 
fixed for 90 mins in formalin. Primary Ab was incubated 1/1000 for 2hr at RT, 
secondary Ab (Santa-Cruz goat anti-rabbit FITC) at 1/500 was incubated at RT for 
1 hr. Cells were mounted on ~1.2% agar pads immobilized within a Gene Frame 
(ABgene) using a 0.13-0.17 mm glass coverslip (VWR). Microscopy was 
performed on an inverted epifluorescence microscope (Zeiss Axiovert 200M) fitted 
with a Plan-Neofluar objective (Zeiss 100x/1.30 Oil Ph3), a 300W xenon arc-lamp 
transmitted through a liquid light guide (Sutter Instruments), and a Sony CoolSnap 
HQ cooled CCD camera (Roper Scientific). All filters were Modified Magnetron ET 
Sets from Chroma and details are available upon request. Digital images were 
acquired and analysed with METAMORPH software (version V.6.2r6). 
 
Proteinase K treatment of whole cells. Cultures of Bt (100 ml) were grown in 
minimal media with heparin (0.5% w/v) as a sole carbon source, to mid exponential 
phase (OD600 ~0.6–0.8; monitored using a Biochrom WPA cell density meter). 
Cells were harvested by centrifugation and washed in 10 ml PBS before being 
resuspended in 5 ml of the buffer. The cells were split into four 1 ml aliquots. To 
three of the aliquots 2 mg/ml Proteinase K was added and incubated at 37 °C for 
1–16 h, the fourth sample was left as an untreated control also for 16 h. Following 
incubation with the protease the samples were centrifuged at 5000 x g for 10 min 
and the supernatant discarded. The cell pellets were resuspended in 1 ml PBS 
and the proteins precipitated by the addition of 200 μl trichloroacetic acid and 
incubation on ice for 30 min. The precipitated proteins were pelleted by 
centrifugation and washed 4 times in 1 ml ice-cold acetone. The protein pellets 
were resuspended in 250 μl Laemmli buffer and subjected to SDS-PAGE. Gels 
were transferred to Whatman Protran BA 85 nitrocellulose membrane. Proteins of 
interest were detected using anti-sera raised in rats against BT4661, BT4662 or 
BT4657. The secondary antibody used was a chicken anti-rat conjugated to 
horseradish peroxidase. Detection was by chemi-luminescence using Biorad 
Clarity Western ECL Substrate. 
 
Co-Immunoprecipitation (Co-IP). Immunoprecipitation was carried out using a 
Pierce Co-IP kit, according to manufacturer’s instructions. Briefly, cells from 30 ml 
of WT Bt grown on MM-heparin to mid-exponential phase were lysed using 
BugBuster (Novagen) and solubilized extract was pre-cleared with control resin. 
The total lysed cell material was passed down an anti-BT4661 antibody column 
(100 μl of agarose resin prepared with 500 μg antibody and crosslinked as per 
manufacturer’s instructions). The column was incubated with gentle rocking at 4 
°C for 16h to pull out BT4661 and any interacting partners from the lysate. The 
column was then washed extensively with Elution buffer (pH 2.8 containing primary 
amines) at 4°C and material remaining bound to the immobilized antibody eluted 
with a low pH buffer. Eluted fractions were neutralized with 1M Tris pH 9.5 and 
anti-BT4661 (raised in rabbit) or anti-BT4659 (raised in rat) antibodies used to 
probe membranes. Detection was by anti-rabbit or anti-rat HRP conjugated 
secondary. 
 
Whole-cell assays. Bt was grown in 5 ml MM with 1% (w/v) of the appropriate 
GAG or glucose as the sole carbon source to mid-exponential phase in glass test 
tubes. Cells were harvested by centrifugation at 5000 x g for 10 min at room 
temperature and washed in 5 ml PBS (pH 7.1) before being resuspended in 1 ml 
PBS. Washed cells were assayed against 10 mg ml-1 of the appropriate GAG at 
37 °C for up to 72 h. Assays were analyzed by thin layer chromatography, 2 μl of 
each sample was spotted onto silica plates and resolved in butanol/formate/water 
(4:8:1) buffer. The plates were dried and sugars visualized using DPA stain. 
 
Recombinant protein production. Genes were amplified by PCR using the 
appropriate primers and the amplified DNA cloned in pET28a using NcoI/XhoI or 
NheI/XhoI restriction sites generating constructs which with either N-terminal or C-
terminal His6 tags. Recombinant genes were expressed with Escherichia coli 
strains BL21 (DE3) or TUNER (Novagen), containing the appropriate recombinant 
plasmid, were cultured to mid exponential phase in LB, supplemented with 50 
µg/ml kanamycin, at 37 °C and 180 rpm. Cells were then cooled to 16 °C and 
recombinant gene expression induced by the addition of 0.1 mM IPTG and cells 
cultured for a further 16 h at 16 °C and 180 rpm. The cells were then centrifuged 
at 5000 x g and resuspended in 10 mM HEPES pH 7.5 with 500 mM NaCl prior to 
being sonicated on ice. Recombinant protein was then purified by immobilized 
metal ion affinity chromatography, using a cobalt-based matrix (Talon, ClonTech) 
and eluted with 100 mM imidazole. For the proteins to undergo structural studies 
(BT1596, BT4661 and BT4656) a further step of size exclusion chromatography 
was employed using a Superdex 16/60 S200 (GE Healthcare), with 10 mM HEPES 
pH 7.5, 500 mM NaCl as the eluent, and were judged to be ≥95 % pure by SDS-
PAGE. Protein concentrations were determined by measuring absorbance at 
280nm using the molar extinction coefficient calculated by ProtParam on the 
ExPasy server (http://web.expasy.org/protparam/). 
 
Isothermal titration calorimetry. The affinity of BT4661SGBP and BT4659SusD-
like for oligo- and polysaccharides was quantified by isothermal titration calorimetry 
(ITC) using a Microcal VP-ITC. The protein sample (50 μM), stirred at 300 rpm in 
a 1.4 ml reaction cell, was injected with 26 x 10 μl aliquots of ligand. Titrations were 
carried out in 20mM Na-HEPES buffer, pH 7.5 at 25 °C. Integrated binding heats, 
minus dilution heat controls, were fit to a single set of sites binding model to derive 
Ka, ∆H and n (number of binding sites on each molecule of protein) using Microcal 
Origin v7.0. The molar concentration of binding sites present in heparin and HS for 
each protein was determined by altering the concentration of ligand used for 
regression of the isotherm until the fit yielded a value of 1 for n. 
 
Small Angle X-ray Scattering (SAXS) experiments. Purified BT4661SGBP (as 
described above) was concentrated to approximately 6 mg/ml using centricon 
devices with a cutoff of 10 kD. For BT4661 in complex with heparin (BT4661L) 1 
mg ml-1 of ligand was added to the protein prior to concentrating the solution. A 
dilution series with buffer at 10 mM HEPES pH 7.5, 250 mM NaCl and 5% glycerol 
was prepared with and without 1 mg ml-1 ligand, to obtain 5 samples covering a 
concentration range from 0.8 mg/ml to 5.9 mg/ml for BT4661 in presence and 
absence of ligand. The protein samples were filtered through a Millex®-GV filter 
with 0.22µm cut-off PVDF membrane before each measurement.  
SAXS experiments were carried out at the X33 beamline of the European 
Molecular Biology Laboratory (Deutsches Electronen Synchrotron, Hamburg) 
using a Pilatus 500K detector. A 4.2 mg/ml solution of bovine serum albumin was 
measured as a reference and for calibration. The scattering patterns were 
measured with an exposure time of 4*30s at 288 K. The wavelength was 1.5 Å. 
The sample-to-detector distance was set at 2.4 m, leading to scattering vectors q 
(defined as q=4π/λ sinθ, where 2θ is the scattering angle) ranging from 0.06Å-1 to 
0.5Å-1. SAXS curves were measured on protein samples with varied 
concentrations in order to check for interparticle interactions. Background 
scattering was measured after each protein sample using the buffer solution and 
then subtracted from the protein scattering patterns after proper normalisation and 
correction from detector response. Absolute calibration was made with a Lupolen 
sample. Experiments were carried out at a temperature of 20°C. 
Scattering Data Analysis. The values of radii of gyration (Rg) were derived from 
the Guinier approximation (1): I(q) = I(0) exp(-q2Rg2/3), where I(q) is the scattered 
intensity and I(0) is the forward scattered intensity. The radius of gyration and I(0) 
are inferred respectively from the slope and the intercept of the linear fit of Ln[I(q)] 
vs q2 in the q-range q.Rg<1.3. The distance distribution function P(r) was 
calculated on the merged curve by the Fourier inversion of the scattering intensity 
I(q) using GNOM (2). All scattering curves were indicative of monomeric states of 
the molecules in solution. The concentration dependence of the Rg value in the 
low q region (Table S4), however, was indicative of slight repulsive interactions of 
the molecules in solution, but otherwise the curves registered at different 
concentrations were perfectly superimposable. The lowest concentration curves 
were considered too noisy and not further taken into account. The estimated Rg 
value from the Guinier-approximation was therefore extrapolated at zero 
concentration for both samples, based on the linear correlation of the four other 
concentrations. A merged curve using the low concentration curve (1.7 mg/ml) in 
the low q region (< 0.085 Å-1) and the high concentration curve (5.9 mg/ml) was 
produced for each of the proteins BT4661 with and without ligand and used in 
subsequent steps. 
The low-resolution shape of BT4661 and BT4661L in solution was determined ab 
initio from the merged scattering curve using the program GASBOR (3). This 
program restores low-resolution shapes of proteins and calculates a volume filled 
with densely packed spheres (dummy residues of 3.8Å diameter) fitting the 
experimental scattering curve by a simulated annealing minimisation procedure 
with a nearest-neighbour distribution constraint. Several independent fits were run 
with no symmetry restriction and the stability and coherence of the solution was 
checked by calculating normalized spatial discrepancy (NSD) values (Table S4) 
using DAMAVER (4). The obtained envelopes were compared to the crystal 
structure by superimposing the objects using PYMOL. CRYSOL (5) was used to 
calculate the fit of the crystal structure (PDB code 4AK1) to the experimental 
scattering curve (Table S4). 
 
Site-directed mutagenesis. Site-directed mutagenesis was conducted using the 
PCR-based QuikChange kit (Stratagene) according to the manufacturer’s 
instructions, using the appropriate plasmid as the template and appropriate primer 
pairs. Mutants of BT4661SGBP were run on native PAGE gels in the presence or 
absence of heparin (0.1% final, added to the gel prior to polymerization) to assess 
their ability to bind the GAG. 
 
Comparative genomics analysis. PULs similar to Bt PULHep were searched for 
in >300 Bacteroidetes genomes. The identification of similar PULs was based on 
a combination of PUL modular alignments and BlastP searches. Gene composition 
and order in all the Bacteroidetes PULs were first computed using the PUL 
predictor described in PULDB (6). Then, the predicted PULs were aligned to 
PULHep according to their modularity as proposed in the RADS/RAMPAGE method 
for protein alignment at the domain level (7). Modules taken into account include 
CAZy families, sensor-regulators, sulfatases and susCD-like genes. Finally, PUL 
boundaries and limit cases were refined by BLASTP-based analysis at the protein 
level. 
 
SUPPLEMENTAL RESULTS 
 
Section 1: BT4657PL12 +1 (active site) specificity: When a mixture of two heavily 
sulphated tetrasacchrides (4 and 5 in Fig. S5B) was treated with BT4657 only 
compound 4 was digested producing Δ4,5UA-GlcNS6S and Δ4,5UA2S-GlcNS6S. 
This suggests that 2-O sulfation is inhibitory to BT4657 but leaves ambiguity if it is 
at the +1 or -2 subsite (the scissile bound is between the sugars at -1 and +1 with 
the non-reducing and reducing end of the substrate extending into the negative 
and positive subsites, respectively (8)). Treatment of the tetrasaccharide mix with 
BT1596, a 2-O sulfatase that specifically removes 2-O sulfate groups from the non-
reducing end of Δ4,5UA, produced a tetrasaccharide (compound 6 in Fig. S5B) 
that was still not cleavable by BT4657. These data demonstrate that BT4657PL12 
cannot tolerate 2-O sulfation of the UA at its +1 subsite and provide a biochemical 
basis for its preference for HS and ΔSHep which contain much lower amounts of 
2-O sulfation than heparin (Fig. S5). 
 
Section 2: Sulfatases biochemical and structural characterization: BT15962S-
sulf and BT46566S-sulf both have a pocket topology with putative metal binding sites 
located at the base of the pocket. In BT15962S-sulf this site comprises D40, H41, 
D299 and H300, whilst in BT46566S-sulf the side chains of D37, D38, D349 and 
Q350 fulfil this role. In both proteins the formylglycine residues and the catalytically 
labile sulfate complete an octa-coordinated geometry of the bound metal. A 
calcium ion could only be modelled into the site of BT46566S-sulf. The importance 
of the metal binding site is demonstrated by the observation that the mutations 
D37A, D38A and D349A in BT4656 and H300A in BT15962S-sulf completely 
inactivated the respective enzymes (Table S8). Neither enzyme could be 
inactivated by EDTA suggesting the metal is either bound extremely tightly or is 
inaccessible to EDTA.  
 
In BT15962S-sulf the O2 sulfate group of the ∆UA makes potential ionic interactions 
with the Nζ of K133 and K312, and hydrogen bonds to Nδ of N101, Nε2 of H196, 
and may make polar contact with the backbone amine of the catalytic residue S72. 
The mutations K133A and N106A caused substantial reductions in catalytic activity 
supporting the important role of the lysine and asparagine in sulfate binding (Table 
S8). E394 interacts with O3 of the unsaturated IdoA and the E394A variant 
displayed a 1000-fold decrease in kcat/Km. Y395 interacts with the glycosidic 
oxygen through its side chain. The Y395A mutation did not affect kcat/Km but 
greatly increased Km and kcat. This suggests the residue contributes to binding but 
not to transition state stabilization, while the commensurate increase in kcat likely 
reflects increased rate of product departure (TableS8). The reducing end GlcNS6S 
makes few interactions with BT15962S-sulf, R245 makes a hydrogen bond to O3 
and a possible ionic interaction with the N2 sulfate both via Nδ2. There is also a 
potential interaction between the O6 sulfate and Nζ of K133. Mutation of R245 to 
Ala had the same effect as the Y395A mutation discussed above, demonstrating 
an important role in substrate binding. The Y395F mutant was completely inactive 
suggesting the more hydrophobic nature of the sidechain prevents substrate 
binding. 
In BT46566S-sulf N98A and K362A mutations both inactivate the enzyme (Table S8). 
N98 sits at the bottom of the active site and interacts with the O6 sulfate via Nδ2. 
K362 potentially hydrogen bonds to the thioester linkage of the O6 sulfate but also 
interacts with D38 of the calcium binding site. Mutation of K362 could potentially 
disrupt the metal binding site and thus the loss of activity of the K362A mutant. 
K125 appears to play an important role in O6 sulfate binding as K125A substitution 
resulted in a 1000-fold reduction in activity. Q147 binds to the endocyclic ring 
oxygen and the O6 sulfate via Nε2 and the Q147A variant causes around a 30 fold 
reduction in activity (Table S8). The importance of the interactions between E446 
and O1 and N2 of the substrate is illustrated by the 1000-fold decrease in activity 
mediated by the E446A mutation. The H447A substitution decreased activity 500-
fold suggesting that H447 is the only residue making productive interactions via 
O3.  
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SUPPLEMENTAL LEGENDS 
 
Supplemental Figure 1. Growth of wild type and mutant strains of Bt on 
heparin, HS and de-O-sulfated heparin. All growths were performed in minimal 
media supplemented with 10mg/ml of the appropriate polysaccharide. OD600nm 
measurements were taken every twenty minutes after bacterial inoculation using 
a plate reader.  
 
Supplemental Figure 2. PULHep distribution and synteny. The key to the color-
coding is shown in the box at the bottom. Genes encoding proteins of unknown 
function are colored grey. Genes are represented above or under the scaffold (bold 
line) to distinguish the coding strain. High distance between the left-most PL13-
coding gene, separated by 5 to 20 genes from the main PUL region, is depicted 
by a double slash interrupting the scaffolds. Homologous proteins across species 
with similar PUL modular arrangement are connected by grey trapezoids. Species 
names are indicated on the right. PUL A and B are used to indicate discrete but 
similar PULs within the same species. 
 
Supplemental Figure 3. Cellular localization of BT4661SGBP, polysaccharide 
lyases encoded by PULHep and key binding residues of BT4661SGBP. (A) 
Immunofluorescence labelling of Glc-grown wild-type or ∆BT4661 cells with anti-
4661 antibody (left panels) or phase contrast (right panels). (B) Western blots 
showing heparin grown whole cells treated with proteinase K and probed with 
polyclonal antibodies raised against recombinant forms of BT4661SGBP, 
BT4662PL12 and BT4657PL12. Proteinase K cannot cross the OM so can only act on 
surface located proteins, revealing that BT4661SGBP and BT4662PL12 are surface 
located, while BT4657PL12 is most likely periplasmic. (C) Co-IP of BT4661SGBP and 
BT4659SusD-like from lysate of heparin grown cells, using anti-BT4461 polyclonal 
antibody immobilised to agarose beads (D) Experimental SAXS curves and the 
fitted scattering profiles calculated by GASBOR. Experimental merged data are 
shown as blue triangles (apo BT4661SGBP) or grey triangles (liganded 
BT4661SGBP).The scattering curves fitted with GASBOR are shown as solid lines. 
lnl, logarithmic representation of Intensity; q, scattering angle in Å-1. (E) Affinity gel 
electrophoresis of BT4661SGBP alanine mutants of residues that interact with the 
fully sulfated heparin-derived hexasaccharide ligand. Upper panel shows native 
gel with no added ligand, lower panel shows native gel with added heparin (0.1% 
final). Loss of retardation of K505A, R581A and R582A on the heparin gel reveals 
these residues are critical in ligand recognition. 
 
Supplemental Figure 4. Density of bound oligosaccharide ligand of 
BT4661SGBP and substrates of the sulfatases and comparison of the active 
sites of the sulfatases with structural homologues. (A) 2Fo-Fc map contoured 
at 1.0 sigma for fully sulfated heparin hexasaccharide in complex with 
BT4661SGBP. (B) (i) 2Fo-Fc map contoured at 1.0 sigma for Δ4,5IdoA2Sβ1-
4GlcNS6S in complex with BT15962S-sulf (ii) and GlcNS6S in complex with 
BT46566S-sulf. (C) Overlay of the sulfatase BT46566S-sulf (green), human 
galactosamine-6-sulfatase (PDB code 4FDI; magenta) BT15962S-sulf (cyan) 
demonstrating the invariability in the catalytic centre.  (D) Overlay of the sulfatase 
BT46566S-sulf (green), 4FDI (cyan) and BT15962S-sulf (magenta) demonstrating 
variability in the glycone binding region. 
 
Supplemental Figure 5. Activity of whole cells and recombinant PULHep 
enzymes against heparin and heparin oligosaccharides and evidence that 
BT4655 is a sulfaminidase. (A) Activity of whole cells and recombinant lysases 
(0.1 μM) against heparin (10 mg/ml). Top panel shows cells grown on glucose 
(Glc) or heparin (Hep) as the sole carbon source to mid-exponential phase, 
washed and assayed against heparin to determine surface enzyme activity. Middle 
and lower panels are products released by recombinant forms of the different PUL 
encoded lyases against heparin. Di and Tet are heparin disaccharide and 
tetrasaccharide standards (structures 2 and 5 in panel B). (B) Identity of the sugars 
labelled in panels C and D. (C) Chromatograms showing sulfate tolerances of 
BT4657PL12 against 4, a sulfated tetrasaccharide lacking a single O2 sulfation, and 
5, a fully sulfated tetrasaccharide, pre and post addition of BT15962S-sulf. (D) 
Chromatograms showing exo-processivity of BT4652PL15 against heparin 
oligosaccharides (all at 50 µM substrate). (E) TLC analysis of, BT4662PL12 and 
BT4657PL12, product profiles against ΔSHep (10 mg/ml) (F) Supernatants of 
stationary phase WT and ΔBT4655NS-Sulf cells grown on heparin. GlcNS lane is a 
standard. 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL TABLES 
 
  Supplemental Table 1. ITC data for BT4659SusD-like and BT4661SGBP.  
Ligand Protein Ka x 104 
(M-1) 
ΔH 
(kcal.mol-1) 
TΔS 
(kcal.mol-1) 
n 
Polysaccharides 
Heparan sulfate BT4659SusD-like 1.4 (±0.6)a -14.0 (±0.3) -8.3 1.0 (±0.01) 
BT4661SGBP 27.0 (±4.0) -9.2 (±0.1) -1.8 1.0 (±0.04) 
Heparin BT4659SusD-like 1.5 (±0.2) -21 (±5.0) -15.3 0.8 (±0.1) 
BT4661SGBP 40.0 (±9.0) -9.7 (±0.3) -2.1 1.0 (±0.02) 
N-Acetyl-de-O-
sulfated heparin 
(ΔSHep) 
BT4659SusD-like 2.1 (±0.4) -9.6 (±0.2) -3.7 0.9 (±0.2) 
BT4661SGBP 11.0 (±8.1) -4.6 (±1.5) 2.3 1.0 (±0.01) 
Heparin oligosaccharides 
Dp2 BT4659 SusD-like NBb    
BT4661SGBP NB    
Dp4 BT4659 SusD-like NB    
BT4661SGBP* 8.5 (±0.4) -6.5 (±0.1) 0.2 0.8 (±0.01) 
Dp6 BT4659 SusD-like NB    
BT4661SGBP* 31.0 (±2.0) -8.3 (±0.1) -0.8 0.8 (±0.01) 
Dp8 BT4659 SusD-like NB    
BT4661SGBP 37.0 (±1.0) -8.7 (±0.2) -1.1 0.7 (±0.01) 
Dp10 BT4659SusD-like NB    
BT4661SGBP* 55.0 (±3.0) -13.0 (±0.1) -5.2 0.5 (±0.01)  
aData are averages and standard deviation of at least two replicates, except in lines 
indicated with *, where data are from a single titration with errors of fit. 
bNB - No binding at maximum concentration tested (1mM for oligosaccharides). 
 
 
 
 
Supplemental Table 2. Crystal data. 
 BT4661 SeMet BT4661 BT4661D5-D6-
Hexasaccharide 
BT1596-Apo BT1596-
UA2SGlcNS6S 
BT4656-GlcNS6S 
Data Collection 01/08/09 15/05/09 27/09/09 22/04/14 10/07/14 04/08/14 
Beamline Diamond light 
source I04 
Diamond light 
source I02 
Diamond light source 
I02 
Diamond light 
source I04-1 
Diamond light 
source I04-1 
Diamond light source 
I04-1 
Cell parameters a=158.78,b=158.678
,c=137.45; α=β=90° 
γ=120° 
a=158.62,b=158.63,
c=137.06; α=β=90° 
γ=120° 
a=52.6,b=68.15,c=85.
14; α=β=γ=90° 
a=68.87,b=68.87,c=
110; α=β= γ=90° 
a=69.21,b=114.535,
c=127.29; α= γ=90° 
β=100° 
a=71.22,b=74.55,c=95; 
α=β=γ=90° 
Space group P6322 P6322 P212121 P41 P21 P212121 
Wavelength (Å) 0.98 0.98 0.98 0.92 0.92 0.92 
Resolution (Å) 51.30-3.10 (3.27-
3.10) 
45.79-1.95 (2.06-
1.95) 
29.77-1.35 (1.42-1.35) 44.53-1.43 
(1.45-1.43) 
46.40-1.90  (1.93-
1.90 ) 
47.50-1.39 (1.41-1.39) 
Rmerge 19.4 (44.7) 0.10 (0.36) 0.04 (0.39) 0.06 (0.72) 0.10 (0.74) 0.07 (0.45) 
Mean I/σI 19.6 (11.0) 10.5 (3.9) 21.8 (4.2) 15.1 (1.6) 9.0 (2.6) 22.8 (5.8) 
CC 1/2 N/A N/A N/A 0.999 (0.908) 0.996 (0.761) 0.995 (0.745) 
Completeness 100 (100) 99.5 (99.5) 98 (97.3) 100 (99.9) (99.6) (76.1) 99.5 (94.7) 
Anomalous 
completeness 
100 (100) - - - - - 
Redundancy 43.4 (45.1) 4.3 (4.3) 6.6 (6.4) 7.3 (4.7) 3.8 (3.9) 7.4 (6.7) 
Anomalous 
redundancy 
23.5 (23.8) - - - - - 
Total reflection 797932 316307 440451 
 
689619 (21786) 587944 (29303) 751944 (31909) 
Total Unique 
reflection 
18386 73908 66383 
 
94403 (4683) 153578 (7607) 101665 (4749) 
Structure 
Refinement 
      
Rwork/Rfree N/A 0.22/0.25 0.16/0.19 0.13/0.16 0.16/0.20 0.11/0.13 
R.M.S.D. N/A      
Bond lengths N/A 0.010 0.013 0.011 0.012 0.011 
Bond Angles N/A 1.21 1.60 1.56 1.53 1.53 
Ramachandran 
plot 
      
Favored (%) N/A 98.3 97.6 97.4 97.4 96.2 
Allowed (%) N/A 99.8 100 99.8 99.8 99.8 
Outliers N/A 0.2 0.0 0.2 0.2 0.2 
Mean B-factor       
Wilson N/A 17.5 16.42 16.51 17.62 9.10 
Main Chain N/A 29.33 16.48 18.78 18.88 9.87 
Side Chain N/A 28.44 21.43 21.19 21.36 11.57 
Ligand/water N/A -/27.05 23.6/28.9 26.48/37.39 40.89/30.62 6.1/25.21 
PDB code N/A 4AK1 4AK2 5G2U 5G2T 5G2V 
Supplemental Table 3. Experimental radius of gyration (Rg), forward 
scattered intensity (I(0)), and maximal distances (Dmax) values, extracted 
from the SAXS curves of BT4661 and BT4661+Ligand (BT4661L). 
 
[BT4661] 
(mg/ml) Rg (Å) 
 I(0)  
0.75 4.33  92  
1.48 4.33  90  
2.87 4.15  90  
4.54 4.05  86  
5.77 4.00  79  
 Extrapol. Rg   
Mw from 
I0 
Rg from P(r) 
Dmax from P(r) 
(Å) 
Bt4661 4.43 78.8 4.58 150 
[BT4661L] 
(mg/ml) Rg (Å) 
 I(0)  
0.78  4.40  96  
1.67 4.30  90  
3.09 4.12  90  
4.52 4.08  93  
5.97 3.98  90  
 Extrapol. Rg 
Mw from 
I0 
Rg from P(r) 
Dmax from P(r) 
(Å) 
Bt4661L 4.43 78.8 4.43 150 
 
 
 
Supplemental Table 4. Calculated χ2 values from fitted experimental 
SAXS curves. 
 
 Rg from Crysol (Å) χ2 Crysol-fita χ2 best Gasbor-
fit 
NSDb SASREFc 
Bt4661 38.6 2.07 0.99 1.62 1.4 
Bt4661L 38.6 4.72 1.00 1.54 2.8 
 
aCrysol-fit using the crystal structure coordinates 4AK1. 
bThe normalized spatial discrepancy (NSD) values were calculated from 5 
independent Gasbor runs. 
cSASREF (9). 
 
 
 
 
Supplemental Table 5. Catalytic activities of the PULHep encoded 
polysaccharide lyases.  
Substrate Enzyme KM (mg.ml) kcat  (min-1) kcat/KM (min-1 mg-1.ml) 
Heparina BT4662PL12 >8 - 325 (±28) 
 BT4657PL12 <0.5 2389 (±463) - 
 BT4675PL13 <0.1 4447 (±54) - 
 BT4652PL15 0.68 (±0.20)  500 (±49) 787 (±234) 
     
HSa BT4662PL12 >2 - 819 (±85) 
 BT4657PL12 0.036 (±0.011) 1193 (±167) 33139 (±9842) 
 BT4675PL13 <0.1 3587 (±68) - 
 BT4652PL15 >2.0 - 740 (±48) 
     
N-acetyl-de-O 
sulfated 
heparin 
(ΔSHep) a 
BT4662PL12 >8 - 120 (±13) 
BT4657PL12 0.079 (±0.002) 1856 (±167) 23512 (±2514) 
BT4675PL13 NAb NA NA 
BT4652PL15 >8 - 0.92 (±0.09) 
  KM (µM) kcat  (min-1) kcat/KM (min-1 M-1) 
Heparin d.p. 4 BT4662PL12 NA NA NA 
 BT4657PL12 NTc NT NT 
 BT4675PL13 - 108 (±15) - 
 BT4652PL15* 4.4 (±0.5) 1023 (±158) 4.9 x 108 (±1.3 x 107) 
     
Heparin d.p. 6 BT4662PL12 NA NA NA 
 BT4657PL12 NT NT NT 
 BT4675PL13 - 1904 (±361) - 
 BT4652PL15 16.5 (±3.1) 2316 (±186) 1.5 x 108 (±2.2 x 107) 
     
Heparin d.p. 8 BT4662PL12 NA NA NA 
 BT4657PL12 NT NT NT 
 BT4675PL13 - 890 (±214) - 
 BT4652PL15* 18.6 (±1.2) 3349 (±56) 1.9 x 108 (±1.1 x 107) 
     
Heparin d.p. 10 BT4662PL12 - - 1.5 x 106 (±3.1 x 105) 
 BT4657PL12 NT NT NT 
 BT4675PL13 NT NT NT 
 BT4652PL15* ≥70 - 3.5 x 107 (±1.2 x 106) 
aPolysaccharide data are in mg.ml. 
bNA indicates no activity detected. 
cNT indicates substrate was not tested. 
Buffer composition was 50mM MES pH 6.0 with 150mM NaCl and 2mM CaCl2. 
*Indicates experiments were technical duplicates. 
 
 
Supplemental Table 6. Lyase end point assays. 
Enzyme(s) Heparin  
(mM per mg) 
HS 
(mM per mg) 
N-acetyl-S 
Heparin (ΔSHep) 
(mM per mg) 
BT4662PL12 0.1 ± 0.004 (5%) 1.0 ± 0.022 (38%) 3.1 ± 0.08 (82%) 
BT4657PL12 0.5 ± 0.01 (27%) 1.4 ± 0.02 (54%) 3.7± 0.06 (100%) 
BT4675PL13 1.7  ± 0.11 (94%) a 1.5 ± 0.04 (56%) N/A 
BT4652PL15 1.7 ± 0.06 (95%) 1.5± 0.002 (58%) Incomplete 
BT4652PL15/BT4675PL13 1.8 ± 0.01 (99%) 1.9 ± 0.02 (71%) - 
BT4652PL15/BT4657PL12 1.7 ± 0.01 (99%) 2.4 ± 0.02 (91%) - 
BT4675PL13/BT4657PL12 1.6 ± 0.07 (93%) 2.1 ± 0.11 (80%) - 
BT4652PL15/BT4662PL12 1.7 ± 0.02 (98%) 2.5 ± 0.22 (93%) - 
BT4662PL12/BT4675PL13 1.4 ± 0.04 (77%) 2.2± 0.04 (84%) - 
BT4662PL12/BT4657PL12 0.5 ± 0.01 (29%) 1.5 ± 0.01 (59%) - 
BT4652PL15/BT4675PL13/BT4657PL12 1.7 ± 0.01 (95%) 2.4 ± 0.02 (92%) - 
BT4652PL15/BT4675PL12/BT4662PL12 1.7 ± 0.05 (95%) 2.2 ± 0.04 (86%) - 
BT4652PL15/BT4657PL12/BT4662PL12 1.8 ± 0.01 (100%) 2.6 ± 0.03 (100%) - 
BT4675PL13/BT4657PL12/BT4662PL12 1.4 ± 0.02 (82%) 2.3 ± 0.02 (89%) - 
BT4652PL15/BT4657PL12/BT4675PL13/ 
BT4662PL12 
1.7 ± 0.01 (95%) 2.5 ± 0.05 (97%) - 
 
a100 % is the maximum digestion observed with any lyase combination for that 
particular GAG and was then used to normalize other values against the same GAG. 
Buffer composition was 50 mM MES pH 6.0 with 150 mM NaCl and 2 mM CaCl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 7. Catalytic activities of the PULHep encoded O-
sulfatases, the GH88 and ROK kinase. 
Substrate Enzyme KM (mM) kcat  (min-1) kcat/KM (min-1 M-1 ) 
 GH88    
UA-GlcNS BT4658 0.1 (±0.002) 2211 (±600) 1.8 x 107  (±4.6 x 106) 
UA-GlcNAc6S BT4658 >0.1 - 1.7 x 107 (±5.1 x 106) 
UA-GlcNAc BT4658 >0.15 - 5.0 x 106  (±2.3 x 105) 
 2O-Sulfatase    
UA2S-GlcNS6S BT1596 0.4 (±0.05) 198 (±34) 5.2 x 106 (±1.2 x 106) 
UA2S-GlcNAc6S BT1596 >100 - 5.5 x 105 (±1.3 x 105) 
UA2S-GlcNAc BT1596 >150 - 3.6 x 105 (±9.5 x 104) 
 6O-Sulfatase    
GlcNAc6S BT4656 - - 2.0 x 105 (±4.0 X 104) 
 ROK-Kinase    
GlcN BT4654 0.2 (±0.02) 4581 (±684) 3.1 x 107 (±3.9 x 106) 
GlcNAc BT4654 4.1 (± 0.4) 3449 (±895) 8.7 x 105  (±3.1 x 105) 
GlcNS BT4654 - - 3.4 x 101 (±1.1) 
Glucose BT4654 114 (±5) 1296 (±238) 1.1 x 104  (±2.1 x 103) 
Mannose BT4654 37 (±9) 867 (±115) 2.4 x 104  (±2.9 x 103) 
ManN BT4654 19 (±4) 33 (±2) 6.2 x 102 (±4.1 x 101) 
ATPa BT4654 0.9 (±0.3) 1954 (±114) 2.4 x 106 (±5.7 x 105) 
 
aValues were determined using GlcNAc as the saturating sugar at concentration of 50 
mM. The buffer used was 100 mM Tris-HCl pH 8.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 8. Activity of mutant variants of BT1596 and BT4656 
O-sulfatases. 
Mutant 
BT15962S-sulf 
kcat/KM  (min-1 M-1) Mutant 
BT46566S-sulf 
kcat/KM  (min-1 M-1) 
BT1596 (S72C) 5.2 x 106 (±1.2 x 106) BT4656 (S77C) 2.0 x 105 (±4.7 x 104) 
S72A NAa S77A NA 
H33A 1.0 x 103 (±5.4 x 101) D37A NA 
N101A 6.6 x 103 (±4.9 x 102) D38A NA 
K133A 1.6 x 104 (±2.6 x 103) N98A NA 
H135A NEb K125A 1.6 x 102 (±1.3 x 101) 
H196A NA H127A NE 
R245A 2.2 x 106 (±1.4 x105) Q147A 6.9 x 103 (±4.6 x 102) 
R246A 2.1 x 103 (±6.8 x 101) H199A NA 
D299A NA R200A 9.8 x 104 (±6.1 x 103) 
H300A NA W249A NE 
K312A NE R266A NE 
Y395A 1.2 x 106 (±1.0 x105) D349A NA 
Y395F NA Q350A NE 
E394A 4.3 x 103 (±5.7 x102) D361A NA 
  K362A NA 
  R363A 2.0 x 102 (±9.9 x 101) 
  E446A 1.1 x 103 (±8.0 x 101) 
  H447A 2.6 x 102 (±2.3 x 101) 
 
aNA indicates no activity detected. 
bNE indicates no expression of recombinant enzyme. 
Substrates used were UA2S-GlcNS6S for BT1596 and GlcNAc6S for BT4656. 
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